Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 17/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16096773 | 0.82 | BUB1 (0.55) | BUB1CHRM1GUCY1A1GUCY1B1 | |
| SCHEMBL16686978 | 0.81 | BUB1 (0.51) | BUB1 | |
| SCHEMBL16693502 | 0.79 | BUB1 (0.68) | BUB1 | |
| SCHEMBL14843837 | 0.76 | BUB1 (0.67) | BUB1 | |
| SCHEMBL13865202 | 0.74 | BUB1 (0.53) | BUB1CHRM1 | |
| SCHEMBL14843520 | 0.74 | BUB1 (0.68) | BUB1 | |
| SCHEMBL6214026 | 0.73 | BUB1 (0.53) | BUB1 | |
| SCHEMBL7816730 | 0.73 | BUB1 (0.54) | BUB1 | |
| SCHEMBL16101539 | 0.73 | BUB1 (0.51) | BUB1GUCY1A1GUCY1B1 | |
| SCHEMBL13865222 | 0.72 | BUB1 (0.48) | BUB1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682974-B2 | Heteroaryl substituted pyrazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-20 | — | — | US | disclosed |
| US-9682974-B2 | Heteroaryl substituted pyrazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-20 | — | — | US | disclosed |
| US-9682974-B2 | Heteroaryl substituted pyrazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-20 | — | — | US | disclosed |
| US-20160326159-A1 | HETEROARYL SUBSTITUTED PYRAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326159-A1 | HETEROARYL SUBSTITUTED PYRAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326159-A1 | HETEROARYL SUBSTITUTED PYRAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | US | disclosed |
| WO-2015063003-A1 | HETEROARYL SUBSTITUTED PYRAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326159-A1 | HETEROARYL SUBSTITUTED PYRAZOLES | CYP3A43, CYP2C19, CYP3A7 | BUB1 2630/4885CHRM1 2933/4885GUCY1A1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.